BriaCell Therapeutics Corp.

11/04/2026

BriaCell Chief Scientific Officer Dr. Miguel A. Lopez-Lago highlights new preclinical findings supporting continued investigation of the Bria-OTS+ cellular immunotherapy platform. The findings will be presented at , November 4–8, in Phoenix, AZ. Find more information: https://bit.ly/47QPjbz

11/03/2026

Join the BriaCell Team!

Briacell Therapeutics is expanding, and we're looking for enthusiastic, driven professionals ready to make a difference in cancer treatment. If you're passionate about biotech innovation and thrive in a collaborative environment, we want to hear from you!

Explore our current opportunities here: https://bit.ly/478ecPX

11/03/2026

BriaCell (Nasdaq: BCTX, BCTXL) (TSX: BCT) and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced four preclinical research presentations at the Society for Immunotherapy of Cancer ( ) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.

The presentations cover BriaCell’s personalized off-the-shelf immunotherapy platform, Bria-OTS+™, and three BriaPro research programs: BP-80, a soluble CD80-Fc fusion protein; TILsRx-001, a tumor-targeted CD80-based checkpoint inhibitor; and engineered CD80 variants with altered immune receptor binding. Find details: https://bit.ly/47QPjbz

11/02/2026

BriaCell CEO Dr. Williams recently spoke with Pulse 2.0 about the company’s approach to cancer immunotherapy, the potential of its off-the-shelf cellular platform, and the future of its clinical pipeline.

The interview explores how BriaCell’s approach aims to combine the precision of personalized medicine with the accessibility of off-the-shelf therapies, including its lead candidate, Bria-IMT, currently being evaluated in a pivotal Phase 3 trial for metastatic breast cancer. Read the full interview: https://bit.ly/3CgzknU

10/29/2026

BriaCell is hiring!

Briacell Therapeutics is expanding our team and looking for passionate, driven individuals to join us in advancing innovative cancer treatments. If you're ready to make a meaningful impact in biotech and work alongside a dedicated team, we'd love to hear from you.

Explore our open roles and take the next step in your career today. https://bit.ly/478ecPX

10/29/2026

Recognizing October as , BriaCell invites you to learn more about key facts and statistics that underscore the importance of continued research and innovation: https://bit.ly/3DgtmSu

October 1 to 31 is Breast Cancer Awareness Month. Get 2026 breast cancer facts, key dates, free resources, and simple ways to take action with NBCF.

10/28/2026

A new Evidence Based Oncology article from American Journal of Managed Care highlights BriaCell’s Bria-IMT™ as an off-the-shelf immunotherapy being evaluated for patients with metastatic breast cancer following treatment with antibody-drug conjugates (ADCs).

The article highlights the ongoing pivotal Phase 3 Bria-ABC study, final Phase 2 data showing a median overall survival of 16.6 months, and recent biomarker findings presented at .

Read the full article: https://bit.ly/3CgzknU

10/26/2026

BriaCell’s Chief Medical Officer, Dr. Giuseppe Del Priore, highlights findings presented at the Congress supporting further evaluation of circulating CAML PD-L1 as a potential biomarker of clinical benefit in metastatic breast cancer. Learn more: https://bit.ly/4yGWuOd

10/23/2026

BriaCell will present new clinical biomarker findings at the Congress highlighting CAML PD-L1 as a potential biomarker of clinical outcomes in metastatic breast cancer.

“We are encouraged by these findings showing that dynamic changes in a circulating immune biomarker were associated with progression-free and overall survival in patients with metastatic breast cancer treated with immunotherapies,” stated Dr. William V. Williams, BriaCell’s President and CEO. For more: https://bit.ly/4yGWuOd

10/23/2026

BriaCell (Nasdaq: BCTX, BCTXL) (TSX: BCT) announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with metastatic breast cancer treated with immune based therapies including the BriaCell regimen at the Congress, taking place October 23-27, 2026 in Madrid, Spain.

The data shown is pooled from several studies including BriaCell’s Phase 1/2 Bria-IMT study. For additional presentation information: https://feeds.issuerdirect.com/news-release.html?newsid=5272554159749348&symbol=BCTX